|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hildebrandt MA, Gu J and Wu X:
Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert
Opin Drug Metab Toxicol. 5:745–755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel D: MicroRNAs: Genomics, biogenesis,
mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie Z, Cai L, Li R, Zheng J, Wu H, Yang X,
Li H and Wang Z: Down-regulation of miR-489 contributes into NSCLC
cell invasion through targeting SUZ12. Tumour Biol. 36:6497–6505.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xia Y, Wu Y, Liu B, Wang P and Chen Y:
Downregulation of miR-638 promotes invasion and proliferation by
regulating SOX2 and induces EMT in NSCLC. FEBS Lett. 588:2238–2245.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ye Z, Yin S, Su Z, Bai M, Zhang H, Hei Z
and Cai S: Downregulation of miR-101 contributes to
epithelial-mesenchymal transition in cisplatin resistance of NSCLC
cells by targeting ROCK2. Oncotarget. 7:37524–37535. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu M, Xue Y, Zheng J, Liu X, Yu H, Liu L,
Li Z and Liu Y: Linc00152 promotes malignant progression of glioma
stem cells by regulating miR-103a-3p/FEZF1/CDC25A pathway. Mol
Cancer. 16:1102017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong Z, Lv M and Chen J: Screening
differential circular RNA expression profiles reveals the
regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in
bladder carcinoma. Sci Rep. 6:309192016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou H and Rigoutsos I: MiR-103a-3p
targets the 5′UTR of GPRC5A in pancreatic cells. RNA. 20:1431–1439.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weber DG, Casjens S, Johnen G, Bryk O,
Raiko I, Pesch B, Kollmeier J, Bauer TT and Brüning T: Combination
of MiR-103a-3p and mesothelin improves the biomarker performance of
malignant mesothelioma diagnosis. PLoS One. 9:e1144832014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen J, Cui JD, Guo XT, Cao X and Li Q:
Increased expression of miR-641 contributes to erlotinib resistance
in non-small-cell lung cancer cells by targeting NF1. Cancer Med.
7:1394–1403. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liao J, Lin J, Lin D, Zou C, Kurata J, Lin
R, He Z and Su Y: Down-regulation of miR-214 reverses erlotinib
resistance in non-small-cell lung cancer through up-regulating LHX6
expression. Sci Rep. 7:7812017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R,
Grannis FW Jr, et al: Non-small cell lung cancer, version 2.2013. J
Natl Compr Canc Netw. 11:645–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bian HB, Pan X, Yang JS, Wang ZX and De W:
Upregulation of microRNA-451 increases cisplatin sensitivity of
non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res.
30:202011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liang W, Wei X, Li Q, Dai N, Li CY, Deng
Y, Jiang X, Tan XR, Dai XY, Li MX, et al: MicroRNA-765 enhances the
anti-angiogenic effect of CDDP via APE1 in osteosarcoma. J Cancer.
8:1542–1551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garofalo M and Croce CM: MicroRNAs as
therapeutic targets in chemoresistance. Drug Resist Updat.
16:47–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boren T, Xiong Y, Hakam A, Wenham R, Apte
S, Wei Z, Kamath S, Chen DT, Dressman H and Lancaster JM: MicroRNAs
and their target messenger RNAs associated with endometrial
carcinogenesis. Gynecol Oncol. 110:206–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo Y, Chen Z, Zhang L, Zhou F, Shi S,
Feng X, Li B, Meng X, Ma X, Luo M, et al: Distinctive microRNA
profiles relating to patient survival in esophageal squamous cell
carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen HY, Lin YM, Chung HC, Lang YD, Lin
CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, et al: miR-103/107
promote metastasis of colorectal cancer by targeting the metastasis
suppressors DAPK and KLF4. Cancer Res. 72:3631–3641. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brewster BL, Rossiello F, French JD,
Edwards SL, Wong M, Wronski A, Whiley P, Waddell N, Chen X, Bove B,
et al: Identification of fifteen novel germline variants in the
BRCA1 3′UTR reveals a variant in a breast cancer case that
introduces a functional miR-103 target site. Hum Mutat.
33:1665–1675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fasihi A, M Soltani B, Atashi A and Nasiri
S: Introduction of hsa-miR-103a and hsa-miR-1827 and hsa-miR-137 as
new regulators of Wnt signaling pathway and their relation to
colorectal carcinoma. J Cell Biochem. 119:5104–5117. 2018.
View Article : Google Scholar : PubMed/NCBI
|
